INDICATIVE OF SUBSTANTIAL COMMUNITY SPREAD. THANK YOU FOR JOINING US TONIGHT. >> IN ORDER TO COMBAT THE SPREAD SCIENTISTS ARE WORKING TO GET MORE SAFE AND EFFECTIVE VACCINES ON THE MARKET. JOHNSON AND JOHNSON IS WORKING ON ONE THAT WOULD ONLY REQUIRE ONE SHOT. WE ARE JOINED LIVE FROM BIOTECHNOLOGIES AT RTP WHERE OTHER POTENTIAL VACCINE PROVIDERS CONDUCTED TRIALS. >> Reporter: THEY ARE CURRENTLY UNDERWAY. ONE OF MANY TRIALS GOING ON RIGHT NOW. THEY NEEDED SOMEONE TO HELP BOTH MANUFACTURED THE VACCINES, AND THAT IS WHERE THEY COME INTO PLAY. >> RIGHT NOW THE FDA HAS ISSUED EMERGENCY USE AUTHORIZATION FOR BOTH PFIZER AND MODERNA VACCINES. BEHIND-THE-SCENES SCIENTISTS ARE WORKING TOWARDS A GOAL OF ADDING MORE TO THE THIS. A CRITICAL NEED TO AMASS ENOUGH SHOTS FOR THE COUNTRY AND THE WORLD. >> WE NEED AS MANY SAFE AND EFFECTIVE VACCINES AS WE CAN GET. >> JOHNSON AND JOHNSON IS WORKING ON A CRITICAL TRIAL. A1 DOSE VACCINE. >> THEY WILL TAKE A VERY CLOSE LOOK AT THE DATA AND SEE IF THEY CAN FORESEE TO BRING THE VACCINE TO MARKET. THAT COULD HAPPEN OVER THE NEXT FEW WEEKS. THAT COULD BE ANOTHER 100 MILLION AMERICANS BY SPRING. >> ASIDE FROM JOHNSON AND JOHNSON, THERE ARE 2 MORE HOPING TO BRING THEIR VACCINES TO THE FRONT LINES. >> THE STUDY STARTED AROUND THE SAME TIME AS THE JOHNSON STUDY. I DO THINK WE CAN ANTICIPATE HEARING SOMETHING ABOUT RESULTS IN THE NEAR FUTURE. THEIR STUDY STARTED ENROLLING IN DECEMBER, BUT THAT STUDY IS ABOUT 30-40% ALREADY ENROLLED. IT IS GOING QUITE WELL. >> EXPERTS TELL US THIS IS PROMISING NEWS. >> IT WILL REALLY PROVIDE ADDITIONAL HOPE THAT WE CAN GET TO A BETTER PLACE.>> Reporter: THE DOCTORS SO SOME OF THE VACCINES IF APPROVED WILL BE